semaglutide and renal failure kidney failure - Ozempic for kidney disease without diabetes semaglutide 1.0 mg once weekly reduced the risk of major kidney disease events by 24 Semaglutide and Renal Failure: A Deep Dive into Kidney Health Outcomes

Ozempic to treat kidney disease The relationship between semaglutide and renal failure has garnered significant attention in recent medical research, particularly for individuals managing type 2 diabetes and chronic kidney disease.2025年1月28日—Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed ... Emerging studies and regulatory approvals indicate that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, offers promising benefits in preserving kidney function and reducing the risk of serious kidney-related outcomes.作者：DJ Leehey·2021·被引用次数：61—Case 2 experienced substantial weight loss (a known effect ofsemaglutide), which may have contributed to the decline inkidney function.

Key Findings and Clinical Evidence:

The landmark FLOW trial has been instrumental in establishing the renal protective effects of semaglutide. This large-scale study demonstrated that semaglutide 1作者：V Perkovic·2024·被引用次数：1509—Semaglutide reduced the risk of clinically important kidney outcomesand death from cardiovascular causes in patients with type 2 diabetes ....0 mg once weekly reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease (CKD)Ozempic (semaglutide) injection is the only GLP-1 RA indicated for adults with T2D and CKD 1 to reduce the risk of sustained eGFR decline, end-stagekidney.... Beyond these kidney benefits, the trial also revealed that semaglutide safeguarded against cardiovascular complications and all-cause mortality, while slowing the annual loss of kidney function.Research shows that Ozempicmay lower the risk of kidney disease-related events by 24% in adults with CKD and Type 2 diabetes. Learn how Ozempic can benefit ...

Further reinforcing these findings, the U.The FLOW of Progress in Diabetic Kidney DiseaseS. Food and Drug Administration (FDA) has expanded the indication for subcutaneous semaglutide (Ozempic) to include the reduction of cardiovascular and kidney disease risks in adults with type 2 diabetes and CKD. This approval is based on evidence showing that semaglutide can lower the risk of kidney failure or serious kidney problems. Specifically, the FDA's decision highlights that individuals receiving a weekly 1mg dose of semaglutide experienced a 24% relative risk reduction of kidney disease progression, kidney failure, and sustained decline in estimated glomerular filtration rate (eGFR).

Research also suggests that semaglutide may be beneficial even in individuals with more advanced CKDEffects of Semaglutide on Chronic Kidney Disease in .... A retrospective study indicated that semaglutide appears to be tolerated by most individuals with CKD 4 or greater, despite the gastrointestinal side effects commonly associated with the drug. Furthermore, in patients with obesity undergoing dialysis, semaglutide treatment resulted in a significant reduction in weight and BMI, while maintaining an acceptable side effect profile.

The SELECT trial also contributed valuable insights, showing that semaglutide decreased the risk for major kidney events by a significant 22% in overweight or obese patients without diabetes, highlighting its broader potential in managing kidney health.Effects of Semaglutide on Chronic Kidney Disease in ...

Mechanisms of Action and Direct Renal Protection:

While the exact mechanisms are still being elucidated, research points to direct renal protection offered by semaglutide. Mouse models of diabetes have shown that semaglutide reduces glomerulosclerosis and renal fibrosis, suggesting an additional pathway beyond blood glucose and blood pressure control. The GLP-1 receptor agonist class, to which semaglutide belongs, has demonstrated pleiotropic effects that may directly benefit kidney cells.

Addressing Concerns and Potential Risks:

While the overall evidence overwhelmingly supports the renal benefits of semaglutide, it's important to acknowledge that like many medications, it can have side effects. There have been some postmarketing reports linking the use of GLP-1 receptor agonists, including semaglutide, with acute kidney injury (AKI).Study links Ozempic to kidney failure prevention However, these instances are considered rare, and many case reports primarily noted AKI with other GLP-1 RAs like exenatide. In the context of the FLOW trial, semaglutide exhibited more frequent acute kidney injuries compared to placebo, though the overall benefit in reducing major kidney outcomes was significant. For patients with renal impairment, including end-stage renal disease, studies have shown no clinically relevant change in semaglutide pharmacokinetics was observed, suggesting that dose adjustments may not typically be necessary.作者：JJ Long·2024·被引用次数：12—Semaglutide appears to be tolerated by most individuals with CKD 4 or greaterdespite associated gastrointestinal side effects similar to those observed in ...

Conclusion:

The scientific and clinical data strongly supports the role of semaglutide in the management of kidney health, particularly for patients with type 2 diabetes and chronic kidney diseaseOzempic approved in Canada to slow kidney disease and .... By significantly reducing the risk of clinically important kidney outcomes and lowering the risk of kidney failure, semaglutide represents a vital therapeutic option. Its ability to slow the progression of kidney disease and safeguard against cardiovascular complications makes it a cornerstone in comprehensive patient care. As research continues, a deeper understanding of these protective mechanisms will further solidify the clinical utility of semaglutide in preserving precious kidney functionFDA Expands Semaglutide Use for CV, Kidney Risks in ....